Raimo Virtanen

1.8k total citations · 1 hit paper
30 papers, 1.5k citations indexed

About

Raimo Virtanen is a scholar working on Cellular and Molecular Neuroscience, Molecular Biology and Physiology. According to data from OpenAlex, Raimo Virtanen has authored 30 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Cellular and Molecular Neuroscience, 14 papers in Molecular Biology and 11 papers in Physiology. Recurrent topics in Raimo Virtanen's work include Neuroscience and Neuropharmacology Research (15 papers), Receptor Mechanisms and Signaling (12 papers) and Neurotransmitter Receptor Influence on Behavior (11 papers). Raimo Virtanen is often cited by papers focused on Neuroscience and Neuropharmacology Research (15 papers), Receptor Mechanisms and Signaling (12 papers) and Neurotransmitter Receptor Influence on Behavior (11 papers). Raimo Virtanen collaborates with scholars based in Finland, United Kingdom and United States. Raimo Virtanen's co-authors include Juha‐Matti Savola, Leena Nyman, Veijo Saano, Ewen MacDonald, Antti Haapalinna, Harry Scheinin, Jouni Sirviö, Mika Scheinin, Risto Lammintausta and Antti Pertovaara and has published in prestigious journals such as Anesthesiology, Molecular Pharmacology and Life Sciences.

In The Last Decade

Raimo Virtanen

30 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Characterization of the selectivity, specificity and potency of medetomidine as an α2-adrenoceptor agonist

1988 572 citations Raimo Virtanen, Juha‐Matti Savola et al. European Journal of Pharmacology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Raimo Virtanen Finland	17	631	466	371	318	285	30	1.5k
Enno Freye Germany	21	480 0.8×	345 0.7×	131 0.4×	253 0.8×	314 1.1×	122	1.3k
Kouichiro Minami Japan	24	331 0.5×	650 1.4×	329 0.9×	639 2.0×	226 0.8×	87	1.7k
Colin S. Goodchild Australia	31	897 1.4×	573 1.2×	222 0.6×	349 1.1×	918 3.2×	77	2.3k
R Virtanen Finland	18	321 0.5×	289 0.6×	370 1.0×	252 0.8×	184 0.6×	26	1.0k
Diederik Nieuwenhuijs Netherlands	16	560 0.9×	158 0.3×	115 0.3×	107 0.3×	249 0.9×	23	1.4k
Tian Z. Guo United States	7	345 0.5×	298 0.6×	75 0.2×	242 0.8×	240 0.8×	9	872
Sakari Karhuvaara Finland	14	255 0.4×	245 0.5×	90 0.2×	108 0.3×	160 0.6×	21	1.1k
Barbara J Pleuvry United Kingdom	18	209 0.3×	328 0.7×	62 0.2×	241 0.8×	183 0.6×	100	1.1k
Vesa Kontinen Finland	32	1.1k 1.7×	826 1.8×	176 0.5×	442 1.4×	1.3k 4.7×	80	3.3k
Tomohiro Yamakura Japan	27	707 1.1×	1.7k 3.7×	110 0.3×	1.3k 4.1×	664 2.3×	62	3.4k

Countries citing papers authored by Raimo Virtanen

Since Specialization

Citations

This map shows the geographic impact of Raimo Virtanen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raimo Virtanen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raimo Virtanen more than expected).

Fields of papers citing papers by Raimo Virtanen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raimo Virtanen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raimo Virtanen. The network helps show where Raimo Virtanen may publish in the future.

Co-authorship network of co-authors of Raimo Virtanen

This figure shows the co-authorship network connecting the top 25 collaborators of Raimo Virtanen. A scholar is included among the top collaborators of Raimo Virtanen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raimo Virtanen. Raimo Virtanen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Leino, Tiina, Timo Viitamaa, Antti Haapalinna, Jyrki Lehtimäki, & Raimo Virtanen. (2009). Pharmacological profile of intrathecal fadolmidine, a α2-adrenoceptor agonist, in rodent models. Naunyn-Schmiedeberg s Archives of Pharmacology. 380(6). 539–550. 12 indexed citations

Lehtimäki, Jyrki, Tiina Leino, Ari Koivisto, et al.. (2008). In vitro and in vivo profiling of fadolmidine, a novel potent α2-adrenoceptor agonist with local mode of action. European Journal of Pharmacology. 599(1-3). 65–71. 23 indexed citations

Pertovaara, Antti, Antti Haapalinna, Jouni Sirviö, & Raimo Virtanen. (2005). Pharmacological Properties, Central Nervous System Effects, and Potential Therapeutic Applications of Atipamezole, a Selective α₂‐Adrenoceptor Antagonist. CNS Drug Reviews. 11(3). 273–288. 83 indexed citations

Haapalinna, Antti, Jouni Sirviö, Ewen MacDonald, Raimo Virtanen, & Esa Heinonen. (2000). The effects of a specific α2-adrenoceptor antagonist, atipamezole, on cognitive performance and brain neurochemistry in aged Fisher 344 rats. European Journal of Pharmacology. 387(2). 141–150. 16 indexed citations

Haapalinna, Antti, Ewen MacDonald, Timo Viitamaa, et al.. (1999). Comparison of the effects of acute and subchronic administration of atipamezole on reaction to novelty and active avoidance learning in rats. Naunyn-Schmiedeberg s Archives of Pharmacology. 359(3). 194–203. 18 indexed citations

Haapalinna, Antti, Timo Viitamaa, Ewen MacDonald, et al.. (1997). Evaluation of the effects of a specific α2-adrenoceptor antagonist, atipamezole, on α1- and α2-adrenoceptor subtype binding, brain neurochemistry and behaviour in comparison with yohimbine. Naunyn-Schmiedeberg s Archives of Pharmacology. 356(5). 570–582. 79 indexed citations

Savontaus, Eriika, Atso Raasmaja, Juha Rouru, et al.. (1997). Anti-obesity effect of MPV-1743 AIII, a novel imidazoline derivative, in genetic obesity. European Journal of Pharmacology. 328(2-3). 207–215. 13 indexed citations

Koulu, Markku, Ullamari Pesonen, Seppo Koskinen, et al.. (1993). Reduced Turnover of Dopamine and 5‐Hydroxytryptamine in Discrete Dopaminergic, Noradrenergic and Serotonergic Rat Brain Areas after Acutely Administered Medetomidine, a Selective α₂‐Adrenoceptor Agonist. Pharmacology & Toxicology. 72(3). 182–187. 14 indexed citations

Jäkälä, Pekka, Timo Viitamaa, Jouni Sirviö, et al.. (1992). Continuous α2-adrenoceptor blockade by atipamezole decreases neocortical high-voltage spindle activity in rats. European Journal of Pharmacology. 221(2-3). 351–357. 10 indexed citations

10.

Savola, Juha‐Matti & Raimo Virtanen. (1991). Central α2-adrenoceptors are highly stereoselective for dexmedetomidine, the dextro enantiomer of medetomidine. European Journal of Pharmacology. 195(2). 193–199. 121 indexed citations

11.

Sirviö, Jouni, P. Riekkinen, Esa Koivisto, et al.. (1991). The effects of atipamezole, an Alpha-2 antagonist, on the performance of young and aged rats in the delayed nonmatching to position task. Pharmacology Biochemistry and Behavior. 39(4). 1015–1019. 11 indexed citations

12.

Maze, Mervyn, et al.. (1991). Effects of Dexmedetomidine, a Novel Imidazole Sedative-Anesthetic Agent, on Adrenal Steroidogenesis. Anesthesia & Analgesia. 73(2). 204???208–204???208. 78 indexed citations

13.

Koulu, Markku, et al.. (1990). 5-HT3 receptor antagonist ondansetron does not alter effects of amphetamine on DA metabolism. Neuroreport. 1(2). 126–128. 2 indexed citations

14.

Koulu, Markku, Ullamari Pesonen, & Raimo Virtanen. (1990). Chronic dexmedetomidine, a selective α2-agonist, decreases serotonin but not noradrenaline turnover in rat brainstem nuclei. European Journal of Pharmacology. 176(2). 151–157. 10 indexed citations

15.

Sjöholm, Birgitta, et al.. (1989). Effects of acute GR38032F (odansetron), a 5-HT3 receptor antagonist, on dopamine and serotonin metabolism in mesolimbic and nigrostriatal dopaminergic neurons. European Journal of Pharmacology. 169(2-3). 321–324. 24 indexed citations

16.

Scheinin, Harry, Raimo Virtanen, Ewen MacDonald, Risto Lammintausta, & Mika Scheinin. (1989). Medetomidine — a novel α2-adrenoceptor agonist: A review of its pharmacodynamic effects. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 13(5). 635–651. 110 indexed citations

17.

Virtanen, Raimo, Juha‐Matti Savola, Veijo Saano, & Leena Nyman. (1988). Characterization of the selectivity, specificity and potency of medetomidine as an α2-adrenoceptor agonist. European Journal of Pharmacology. 150(1-2). 9–14. 572 indexed citations breakdown →

18.

Scheinin, Harry & Raimo Virtanen. (1986). Effects of yohimbine and idazoxan on monoamine metabolites in rat cerebrospinal fluid. Life Sciences. 39(16). 1439–1446. 19 indexed citations

19.

Virtanen, Raimo, et al.. (1986). Effect of Detomidine on the Release and Turnover of Noradrenaline in Rat Brain. Acta Pharmacologica et Toxicologica. 58(5). 348–354. 2 indexed citations

20.

Virtanen, Raimo, E Iisalo, Martti Parvinen, & E Nordman. (1979). Methotrexate Concentrations in Biological Fluids: Comparison of Results Obtained by Radioimmunoassay and Direct Ligand Binding Radioassay. Acta Pharmacologica et Toxicologica. 44(4). 296–302. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact